Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ERAS-801 |
| Synonyms | |
| Therapy Description |
ERAS-801 is an EGFR inhibitor with improved blood-brain barrier penetrating ability, potentially leading to inhibition of growth of EGFR-overexpressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ERAS-801 | ERAS801|ERAS 801 | EGFR Inhibitor (Pan) 63 | ERAS-801 is an EGFR inhibitor with improved blood-brain barrier penetrating ability, potentially leading to inhibition of growth of EGFR-overexpressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07089641 | Phase I | ERAS-801 | ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial (ERAS801-SARG) | Recruiting | USA | 0 |
| NCT05222802 | Phase I | ERAS-801 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Active, not recruiting | USA | 0 |